home.social

#bonumce — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #bonumce, aggregated by home.social.

  1. 4/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc

    ⌚️Understanding timing of onset helps us better understand, differentiate, & manage TKI & ICI-related AEs 👇

  2. 5/#TumorBoardTuesday #BonumCE #OncTwitter #GynCSM #gynonc #EndometrialCancer
    #CME 🔗bit.ly/3YRDkog

    🟢#PreTest Q 4️⃣
    📊During treatment w pembro + lenva, pt develops grade 3 HTN
    🟢What is the most effective mgmt strategy for this patient? (CS = corticosteroid)

  3. 17/#TumorBoardTuesday #BonumCE #RenalCell
    #OncTwitter #NephTwitter #MedTwitter

    🔬Research needed to ⬇️ tox while maintaining efficacy

    ❓Alternative dosing strategies (incl. dose breaks)
    ❓Effects of dose ⬇️ on pt outcomes
    ❓Effects of reduced ▶️ dose on pt outcomes

  4. 15/ #TumorBoardTuesday #BonumCE #RenalCell
    #OncTwitter #NephTwitter #MedTwitter

    🟢Pt w mRCC
    🔸Initiated tx w pembro + lenva
    🔹Developed G3 diarrhea
    🔸Lenva withheld & anti-diarrheal treatment initiated 🔹Diarrhea now resolved.

    🟢What next step is best for the pt?

  5. 14/#TumorBoardTuesday #BonumCE #RenalCell
    #OncTwitter #NephTwitter #MedTwitter

    Effective tox mgmt ➡️optimize pt outcomes✅

    🩺 Mgmt strategies include...🩺
    🔹Prevention
    🔸Monitor BP, urine protein, thyroid & liver function
    🔹Dose modification (⏸️⬇️🛑)
    🔸Supportive care

  6. 13/#TumorBoardTuesday #BonumCE #RenalCell
    #OncTwitter #NephTwitter #MedTwitter

    🔬Common tox in pivotal P3 #CHECKMATE214 trial of dual ICI combo🔬
    🔸Fatigue
    🔹Pruritus
    🔸Diarrhea
    🔹Rash
    🔸Nausea

  7. 12/#TumorBoardTuesday #BonumCE #RenalCell
    #OncTwitter #NephTwitter #MedTwitter

    🔬Common tox in pivotal Phase 3 trials of TKI-ICI combos🔬
    #KEYNOTE426 #CLEAR #CHECKMATE9ER #JAVELINrenal101
    🔹Diarrhea
    🔸HTN
    🔹Hypothyroidism
    🔸Fatigue
    🔹PPES
    🔸Loss of appetite

  8. 7/ #TumorBoardTuesday #BonumCE #RenalCell
    #OncTwitter #NephTwitter #MedTwitter

    🟢Which of the following is a characteristic feature of the most common toxicities associated with anti-angiogenic therapies?

  9. 8/#TumorBoardTuesday #BonumCE #RenalCell

    Combo tx =possible⬆️tox➡️can lead to trtmnt🛑

    ✨Anti-angio inhibitors=multi🎯TKIs
    ✨AEs related to shared 🎯s (e.g. VEGFR)=predictable class tox
    ✨Some nuance due 2 diff🎯/potency
    ✨Typ occur 1st few wks of ▶️tx
    ✨Broadly dose-dependent

  10. 6/ #TumorBoardTuesday #BonumCE #OncTwitter #NephTwitter #MedTwitter #RenalCell

    ✳️Dual ICI combo (ipi + nivo) also approved tx option

    💎#CheckMate214 - ipi + nivo vs sunitinib
    ✅Longest follow-up in frontline RCC (>5 years)
    ✅OS and PFS favor combo tx in int/poor risk pts

  11. 4/ #TumorBoardTuesday #BonumCE #OncTwitter #RenalCell

    💎Combo txs as SOC for 1st line mRCC💎

    TKI/ICI combos:
    🔸#lenvatinib (TKI) + #pembrolizumab (PD-1 mAb)
    🔸#axitinib (TKI) + pembro
    🔸#cabozantinib (TKI) + #nivolumab (PD-1 mAb)

    Dual ICI combo:
    🔸#ipilimumab (CTLA-4) + nivo

  12. 4/ #TumorBoardTuesday #BonumCE #OncTwitter #RenalCell

    💎Combo txs as SOC for 1st line mRCC💎

    TKI/ICI combos:
    🔸#lenvatinib (TKI) + #pembrolizumab (PD-1 mAb)
    🔸#axitinib (TKI) + pembro
    🔸#cabozantinib (TKI) + #nivolumab (PD-1 mAb)

    Dual ICI combo:
    🔸#ipilimumab (CTLA-4) + nivo

  13. 4/ #TumorBoardTuesday #BonumCE #OncTwitter #RenalCell

    💎Combo txs as SOC for 1st line mRCC💎

    TKI/ICI combos:
    🔸#lenvatinib (TKI) + #pembrolizumab (PD-1 mAb)
    🔸#axitinib (TKI) + pembro
    🔸#cabozantinib (TKI) + #nivolumab (PD-1 mAb)

    Dual ICI combo:
    🔸#ipilimumab (CTLA-4) + nivo